期刊文献+

RP-HPLC法测定人血浆中帕利哌酮的浓度 被引量:2

Determination of Paliperidone in Human Plasma by RP-HPLC
原文传递
导出
摘要 目的:建立测定人血浆中帕利哌酮浓度的方法。方法:血样以乙醚处理后采用反相高效液相色谱法进样测定。色谱柱为Agilent Eclipse Plus C18,流动相为甲醇-乙腈-水(1∶5∶14,加入1.88%正丁胺以及1.80%冰醋酸),流速为1.0 ml/min,检测波长为280nm,温度为室温(18~28℃),内标为曲唑酮,湿度<85%。结果:帕利哌酮血药浓度在2.81~180 ng/ml范围内线性关系良好(r=0.999 0);平均方法回收率在99.01%~104.23%之间,日内、日间RSD均<11%。结论:该法操作简便、准确、重复性好,可用于临床监测帕利哌酮的血药浓度。 OBJECTIVE: To establish a method for determining the plasma concentration of paliperidone. METHODS: RP-HPLC method was adopted after samples were treated with ethyl ether using trazodone as internal standard. The determination was performed on Agilent Eclipse Plus C^8 column with mobile phase consisted of methanol-acetonitrile-water (1:5:14 added into 1.88% n-butylamine and 1.80% glacial acetic acid) at flow rate of 1.0 ml/min. The detection wavelength was set at 280 nm and room temperature maintained at 18-28 %. The relative humidity was kept less than 85%. RESULTS: The liner range of palisperi- done were 2.81-180 ng/ml (r=0.999 0) with recovery of 99.01%-104.23%. RSDs of inter-day tests and intra-day were lower than 11%. CONCLUSIONS: The method is simple, accurate and reproducible, and can be used for the determination of plasma concentration of palisperidone in the clinic.
出处 《中国药房》 CAS CSCD 2014年第30期2819-2820,共2页 China Pharmacy
关键词 帕利哌酮 反相高效液相色谱法 药动学 血药浓度 Paliperidone RP-HPLC Pharmacokintics Plasma concentration
  • 相关文献

参考文献7

  • 1司天梅.新型抗精神病药帕利哌酮缓释剂[J].中华精神科杂志,2010,43(2):118-120. 被引量:39
  • 2Kane J, Canas F, Kramer M, et aI. Treatment of schizo- phrenia with paliperidone extended-release tablets: a 6-week placebo-controlled trial[J]. Schizophr Res, 2007, 90(1/3) : 147.
  • 3Marder SR, Kramer M, Ford L, et al. Efficacy and safe- ty of paliperidone extended-release tablets: results of a 6-week, randomized, placebo-controlled study[J]. Biol Psychiat, 2007, 62 (12) : 1 363.
  • 4Davidson M, Emsley R, Kramer M, et al. Efficacy, safe- ty and early response of paliperidone extended-release tab- lets (paliperidone ER) : results of a 6-week, random- ized, placebo-controlled study[J]. Schizophr Res, 2007, 93(1/3) : 117.
  • 5夏又华,唐曦阳,朱艳.LC/MS/MS分析人血浆中利培酮和9-OH-利培酮的浓度[J].中医药导报,2006,12(5):67-69. 被引量:2
  • 6Remmerie BMM, Sips LLA, Vries R de, et al. Validated method for the detemination of rispedone and 9-hydroxy- riperidone in human plasma by liquid chromatogrn- phy-tandem mass spectrometry[J]. J Chrornatogr B, 2003, 783(2) :461.
  • 7Aravagiri M, Marder RS. Simultaneous detemination of risperidone and 9-hydroxyrisperidone in plasma by liquid chromatography/eleetrospray tandem mass spectrometry [J]. J Mass Spectrom, 2000, 35: 718.

二级参考文献17

  • 1Conley R,Gupta SK,Sathyan G.Clinical spectrum of the osmotic-controlled release oral delivery system (OROS),an advanced oral delivery form.Curr Med Res Opin,2006,22:1879-1892.
  • 2Dremencov E,El Mansari M,Blier P.Distinct electrophysiological effects of paliperidone and risperidone on the firing activity of rat serotonin and norepinephrine neurons.Psychopharmacology (Berl),2007,194:63-72.
  • 3Mannens G,Huang ML,Meuldermans W,et al.Absorption,metabolism,and excretion of risperidone in humans.Drug Metab Dispos,1993,21:1134-1141.
  • 4Schotte A,Janssen PF,Gommeren W,et al.Risperidone compared with new and reference antipsychotic drugs:in vitro and in vivo receptor binding.Psychopharmacology(Berl),1996,124(1-2):57-73.
  • 5Ejsing TB,Pedersen AD,Linnet K.P-glycoprotein interaction with risperidone and 9-OH-risperidone studied in vitro,in knock-out mice and in drug-drug interaction experiments.Hum Psychopharmacoll,2005,20:493-500.
  • 6Kirschbaum KM,Henken S,Hiemke C,et al.Pharmacodynamic consequences of P-glycoprotein-dependent pharmacokinetics of risperidone and haloperidol in mice.Behav Brain Res,2008,188:298-303.
  • 7Van Beijsterveldt LE,Geerts RJ,Leysen JE,et al.Regional brain distribution of risperidone and its active metabolite 9-hydroxyrisperidone in the rat.Psychopharmacology (Berl),1994,114:53-62.
  • 8Arakawa R,Ito H,Takano A,et al.Dose-finding study of paliperidone ER based on striatal and extrastriatal dopamine D2 receptor occupancy in patients with schizophrenia.Psychopharmacology(Berl),2008,197:229-235.
  • 9Kapur S,Seeman P.Does fast-dissociation from the dopamine d(2) receptor explain the action of atypical antipsychotics? A new hypothesis.Am J Psychiatry,2001,158:360-369.
  • 10Seeman P.An update of fast-off dopamine D2 atypical antipsychotics.Am J Psychiatry,2005,162:1984-1985.

共引文献39

同被引文献23

  • 1中华医学会.精神分裂症防治指南[M].北京:北京大学医学出版社,2007,55:26.
  • 2Gopal S,Vijapurkar U,Lim P,et al.A 52-week open-label study of the safety and tolerability of paliperidone palmitate in patients with schizophrenia[J].J Psychopharmacol,2010,25(5):685.
  • 3Nussbaum AM,Stroup TS.Paliperidone palmitate for schizophrenia[J].Schizophr Bull,2012,38(6):1 124.
  • 4Hiemke C,Baumann P,Bergemann N,et al.AGNP consensus guidelines for therapeutic drug monitoring in psychiatry:update 2011[J].Pharmacopsychiatry,2011,44(6):195.
  • 5de Leon J,Wynn G,Sandson NB.The pharmacokinetics of paliperidone versus risperidone[J].Psychosomatics,2010,51(1):80.
  • 6Lee J,Jiang J,Sim K,et al.Gender differences in Singaporean Chinese patients with schizophrenia[J].Asian J Psychiatr,2011,4(1):60.
  • 7Takeuchi K,Sanjo K,Sakai A.Paliperidone,risperidone[J].Nihon Rinsho,2013,71(4):654.
  • 8鱼爱和,张小澍,邓鸣.非典型抗精神病药物不良反应的性别差异[J].药物不良反应杂志,2008,10(2):110-115. 被引量:18
  • 9喻东山.帕利哌酮的不良反应[J].临床荟萃,2011,26(2):173-177. 被引量:7
  • 10管丽丽,杜立哲,马弘.精神分裂症的疾病负担(综述)[J].中国心理卫生杂志,2012,26(12):913-919. 被引量:196

引证文献2

二级引证文献10

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部